Noxygen AntiGen (ARA-290) 15mg Nasal Spray 10ml

AntiGen (ARA-290) is a highly promising compound that has demonstrated remarkable potential for enhancing tissue repair and reducing inflammation in a variety of conditions. A prominent member of the erythropoietin (EPO) family, ARA-290 successfully emulates the protective and reparative effects of EPO while effectively bypassing its undesirable side effects.
This synthetic peptide, ARA290, contains 11 amino acids and was originally developed to treat neuropathic pain, a common condition characterized by chronic nerve pain caused by injury. However, its enormous potential for tissue repair and anti-inflammatory properties has attracted considerable attention in recent years and has been the subject of numerous animal studies.
AntiGen works through the EPO receptor, which is found in various tissues, including the brain, heart, kidneys, and liver. Binding of the ARA 290 peptide to the EPO receptor triggers downstream signals that promote cell survival, proliferation, and differentiation, thereby facilitating tissue repair and regeneration.
Furthermore, AntiGen nasal spray has notable anti-inflammatory properties. It suppresses the production of proinflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and interleukin-1 beta (IL-1β), while stimulating the secretion of anti-inflammatory cytokines such as interleukin-10 (IL-10). This dual modulatory effect positions ARA-290 nasal spray as a highly promising compound for a variety of conditions associated with tissue damage and inflammation.

Effects:
- Improved blood vessel health;
- Reduction of inflammatory cytokines;
- Tissue protection;
- Relief of neuropathic pain;
- Immune system support;

100-400 mcg per day, 1-4 sprays, 1-3 months

Consult a sports medicine physician before use. Not for use by individuals under 21 years of age or pregnant women (including lactating women).

Store in the refrigerator at 2-5 degrees Celsius.
When stored at room temperature, the peptide can remain viable for up to 1 month.